{
    "clinical_study": {
        "@rank": "43555", 
        "acronym": "ECLS", 
        "arm_group": [
            {
                "arm_group_label": "Control", 
                "arm_group_type": "No Intervention", 
                "description": "participants monitored for 10 years for lung cancer incidence."
            }, 
            {
                "arm_group_label": "Early CDT Lung Test", 
                "arm_group_type": "Active Comparator", 
                "description": "Early CDT lung blood test"
            }
        ], 
        "brief_summary": {
            "textblock": "AIMS HYPOTHESIS In a high risk population the EarlyCDT-Lung test reduces the incidence of\n      late stage tumours;3 / 4 / Unclassified (U) at diagnosis compared to normal clinical\n      practice.\n\n      AIMS To assess the effectiveness of EarlyCDT-Lung test in increasing early stage lung cancer\n      detection, thereby reducing the rate of late stage (3 / 4 / U) presentation, compared to\n      normal clinical practice; to assess the cost-effectiveness of EarlyCDT-Lung test compared to\n      normal clinical practice; to assess the effectiveness of EarlyCDT-Lung test in reducing\n      adverse outcomes including potential psychological and behavioural consequences."
        }, 
        "brief_title": "Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung Test", 
        "condition": "Lung Cancer", 
        "condition_browse": {
            "mesh_term": "Lung Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Participant is willing and able to give informed consent for participation in the\n             study\n\n          2. Male or female aged 50 years to 75 years\n\n          3. Current or Ex-smoker with at least 20 year pack history\n\n          4. or Less than 20 year pack history but with family history of lung cancer in a 1st\n             degree relative (mother, father, sister, brother, child)\n\n          5. ECOG Status: 0, 1 and 2 (Eastern Co-operative Oncology Group) Grade ECOG 0 Fully\n             active, able to carry on all pre-disease performance without restriction 1 Restricted\n             in physically strenuous activity but ambulatory and able to carry out work of a light\n             or sedentary nature, e.g., light house work, office work 2 Ambulatory and capable of\n             all self-care but unable to carry out any work activities. Up and about more than 50%\n             of waking hours\n\n          6. Geographical postal sectors of:\n\n        NHS Geographical Area  Eligible Postcodes Tayside DD1 - DD11 (except DD6), PH1-PH3 ,\n        PH6-PH8, PH10, PH11, PH13, PH15 & PH16 Greater Glasgow & Clyde G1-G5, G11 -G15, G20-G22,\n        G31-34, G40 -G46, G51- G53, G60-G62 &G64, G66 & G69, G72 & G73, G76-G78, G81-G83 PA1-PA8\n        (except PA6), PA11-PA16 & PA19\n\n        Exclusion Criteria:\n\n          1. History of any cancer other than non-melanomatous skin cancer, cervical cancer in\n             situ.\n\n          2. Symptoms suggestive of lung cancer within past 6 months (haemoptysis, unintentional\n             weight loss (at least 5% in preceding 6 months).\n\n          3. Patients for whom the GP considers invitation to the study would cause undue\n             distress.\n\n          4. Patients with other terminal disease.\n\n          5. Patients on prolonged / continuous use (> 3months) of cytotoxic/ immuno-suppressant\n             drugs eg: Methotrexate, Cyclophosphamide, Azathioprine, Rapamycin, Mycophenolate,\n             Rituximab and anti-immunophilins such as Ciclosporin, Tacrolimus. Monotherapy using\n             glucocorticoids/ steroids eg  prednisolone is NOT an  exclusion criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "10000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01925625", 
            "org_study_id": "2013ON07"
        }, 
        "intervention": {
            "arm_group_label": "Early CDT Lung Test", 
            "description": "The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.", 
            "intervention_name": "Early CDT Lung blood test", 
            "intervention_type": "Biological", 
            "other_name": "EarlyCDT-Lung test"
        }, 
        "intervention_browse": {
            "mesh_term": "Autoantibodies"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 19, 2013", 
        "link": {
            "url": "http://www.eclsstudy.org"
        }, 
        "location": [
            {
                "contact": {
                    "email": "s.gallant@dundee.ac.uk", 
                    "last_name": "Stephanie L Gallant", 
                    "phone": "01382 383994"
                }, 
                "contact_backup": {
                    "email": "r.littleford@dundee.ac.uk", 
                    "last_name": "Roberta C Littleford", 
                    "phone": "01382 383242"
                }, 
                "facility": {
                    "address": {
                        "city": "Dundee", 
                        "country": "United Kingdom", 
                        "state": "Tayside", 
                        "zip": "DD1 9SY"
                    }, 
                    "name": "NHS Tayside"
                }, 
                "investigator": {
                    "last_name": "Frank Sullivan", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "karen.duffy@ggc.scot.nhs.uk", 
                    "last_name": "Karen Duffy", 
                    "phone": "0141 2329525"
                }, 
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "NHS Greater Glasgow & Clyde"
                }, 
                "investigator": {
                    "last_name": "Frances Mair", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung Test", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "difference at 24 months after randomisation, between the number of patients with stage 3, 4 or unclassified lung cancer at diagnosis in the intervention arm, and those in the control arm;", 
            "measure": "to assess the effectiveness of EarlyCDT-Lung test in reducing the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical practice;", 
            "safety_issue": "No", 
            "time_frame": "24 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01925625"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Dundee", 
            "investigator_full_name": "Cheryl Hume", 
            "investigator_title": "TCTU Administrator", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "University of Dundee", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cheryl Hume", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}